
Quantum X Labs Inc. reported a 37% drop in third-quarter revenue to $254,000, down from $401,000 in the same period last year. The decline came as the company’s operating loss nearly quadrupled to $5.879 million, up from $1.148 million.
The company, based in Ramat Gan, Israel, previously operated under the name Viewbix. Its stock (NASDAQ: QXL) closed at $3.21 on November 18, following the filing of its quarterly report. The SEC accepted the submission at 4:16 p.m. EST, after market close. Trading for Quantum X Labs shares had already ended at 4:00 p.m. EST that day.
Revenue and Cost Pressures
Traffic acquisition costs rose to $147,000 in the third quarter, up from $59,000, absorbing 58% of revenue, compared to 15% last year. Over nine months, traffic costs increased to $413,000 from $243,000, representing 46% of total revenue, versus 19% the prior year.
General and administrative expenses became the largest operating cost, climbing to $1.102 million from $435,000. Depreciation and amortization rose to $598,000 from $241,000. These increases accounted for roughly two-thirds of the expanded operating loss.
Research and development spending increased to $150,000 in the quarter, up from $21,000. Over nine months, R&D costs reached $335,000, compared to $57,000.
Read Also: Apollo Silver launches deep drilling at California silver project
Financial Shifts and Shareholder Impact
A $3.84 million loss from deconsolidating CliniQuantum contributed to the quarter’s financial strain. The deconsolidation accounted for most of the September 2026 quarter’s $6.001 million loss from continuing operations before taxes. Quantum X Labs recorded $73,000 as its share of losses from associates. Net financial expenses fell to $40,000 from $645,000, offsetting part of the operating loss increase.
Over nine months, the loss from continuing operations narrowed to $4.067 million from $12.729 million. Net financial expenses dropped to $224,000, offsetting the rise in operating losses, which grew to $3.993 million from $1.603 million. The 2025 quarter included a $2.805 million loss from discontinued operations, bringing the total net loss to $3.953 million—$560,000 attributable to non-controlling interests.
The basic loss per share from continuing operations widened to $0.28, up from $0.11. The weighted-average share count rose to 21.3 million from 10.5 million, after a reverse stock split. Adjustments to prior-year figures were made retroactively. When discontinued operations were included, the total basic loss per share narrowed to $0.28 from $0.32. The company noted that share and per-share data for periods preceding the reverse stock split had been retrospectively adjusted.
Quantum X Labs’ fiscal year ends December 31, with fourth-quarter results expected to finalize its 2026 revenue total. Through September 30, revenue stood at $900,000, down from $1.3 million in the same period last year.